Abstract 4691
Background
Acute promyelocytic leukemia (APL) is strongly related to obesity. APL patients have significantly higher body mass index (BMI) than other acute leukemia. In APL patients, BMI over 30 kg/m2 is reported to be a risk factor of all trans retinoic acid (ATRA) induced differentiation syndrome (DS), and associated with inferior disease free survival (DFS) and overall survival (OS). We assessed the impact of obesity associated various factors on APL clinical course.
Methods
We retrospectively reviewed clinical records of the APL patients in our center since January 2008 to May 2019. We used Fisher’s exact test in univariate analysis, logistic regression in multivariate analysis, logrank test in survival analysis.
Results
51 patients were included in this study. The median age was 57 (range: 19-88), 24 females and 27 males. The median BMI was 23.1, 8 (15%) had BMI over 30 kg/m2. All patients were administered ATRA only or ATRA plus anthracycline based chemotherapy. 35 (68%) developed DIC at diagnosis, 18 (35%) developed DS by ATRA administration.47 (92%) achieved complete remission, median suvival was 1304 days (1-6608).9 (17%) experienced relapse.8 (15%) were died by bleeding, another cancer, organ failure. BMI over 30 kg/m2 was associated with high visceral and subcutaneous fat volume(P = 0.01, respectively). High triglyceride (TG) and LDL-cholesterol were independent of high BMI (P = 0.67, =0.54, respectively). In univariate and multivariate analysis, only high TG (over 150 mg/dl) was significantly associated with DIC (odds ratio (OR)= 10.6 (1.6-126.0), p = 0.004, OR = 11.6 (1.9-67.5), p = 0.006, respectively) and DS (OR = 7.31 (1.1-84.2), p = 0.02, OR = 7.7 (1.3-44.0), p = 0.02). BMI, TG, LDL, visceral or subcutaneous fat volume were not significantly affect with OS and DFS. DS onset or high white blood cell count were associated with inferior OS (P = 0.03) or PFS (P = 0.01).
Conclusions
High TG was a major risk factor of DIC and DS in APL treatment. It is possible that TG metabolic pathway will be linked to DIC and DS pathogenesis. Low fat diet or hyperlipidemia treatment may decrease DIC and DS progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4125 - DUBLIN-3, a Stage IIIb/IV NSCLC Phase (Ph)3 Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone
Presenter: Ramon Mohanlal
Session: Poster Display session 1
Resources:
Abstract
3345 - Escalation plans and DNACPR discussions in the unwell oncology patient
Presenter: Raghad Elghadi
Session: Poster Display session 1
Resources:
Abstract
4165 - The Relation between the Symptom Burden of Hospitalized Patients with Incurable Cancer and the Quality-of-Life of Their Family Caregivers
Presenter: Eman Tawfik
Session: Poster Display session 1
Resources:
Abstract
1784 - Clinical predictors for analgesic response to radiotherapy in patients with painful bone metastases
Presenter: Ragnhild Habberstad
Session: Poster Display session 1
Resources:
Abstract
5323 - 30-Day Mortality in Palliative Radiotherapy
Presenter: Shing Fung Lee
Session: Poster Display session 1
Resources:
Abstract
3942 - The relationship between Naldemedine administration and the maximum dose of oral opioids
Presenter: Shinya Kajiura
Session: Poster Display session 1
Resources:
Abstract
3698 - Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30.
Presenter: Elizabeth Santana
Session: Poster Display session 1
Resources:
Abstract
3885 - Olanzapine Combined with 5-HT3 RA Plus Dexamethasone for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in High and Moderate Emetogenic Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Presenter: Jian-Guo Zhou
Session: Poster Display session 1
Resources:
Abstract
5700 - Early Palliative care in advanced cancer, is it really effective?
Presenter: Raquel Gómez Bravo
Session: Poster Display session 1
Resources:
Abstract
5924 - Deprescribing Potentially Inappropriate Medication in Cancer Patients
Presenter: Simon Reuter
Session: Poster Display session 1
Resources:
Abstract